Ki-hong Jang
Daejeon, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Preclinical Pharmacokinetics of DM5167, a Novel Selective PARP1 Inhibitor.
Journal: Pharmaceutical research
Published: June 16, 2025
Pharmacological Intervention Targeting FAF1 Restores Autophagic Flux for α-Synuclein Degradation in the Brain of a Parkinson's Disease Mouse Model.
Journal: ACS chemical neuroscience
Published: March 01, 2022
Protective effects of PARP1-inhibitory compound in dry age-related macular degeneration.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 23, 2020
Protective effect of RIPK1-inhibitory compound in in vivo models for retinal degenerative disease.
Journal: Experimental eye research
Published: June 18, 2018
A novel RIPK1 inhibitor that prevents retinal degeneration in a rat glaucoma model.
Journal: Experimental cell research
Published: July 13, 2017
Kinase-independent role of nuclear RIPK1 in regulating parthanatos through physical interaction with PARP1 upon oxidative stress.
Journal: Biochimica et biophysica acta. Molecular cell research
Published: March 25, 2017
AIF-independent parthanatos in the pathogenesis of dry age-related macular degeneration.
Journal: Cell death & disease
Published: August 10, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026